Stay informed with the latest litigation news. Explore now

IP Verse

Revance Therapeutics competitive analysis

Latest publications and patents of Revance Therapeutics New

Explore the latest publications and patents granted to Revance Therapeutics, showcasing their recent innovations and technological advancements.

Last updated on: Sep 2, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Revance Therapeutics

EP2490986
Apr 24, 2024Methods And Systems For Purifying Non-Complexed Botulinum NeurotoxinPatent Maintained As Amended
EP3368071
Jan 26, 2022Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic EffectGranted And Under Opposition
EP2661276
Aug 2, 2017Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin CompositionsRevoked

Latest patents of Revance Therapeutics opposed by its competitors

Explore Revance Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 4, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2490986
Apr 24, 2024Methods And Systems For Purifying Non-Complexed Botulinum Neurotoxin1
EP3368071
Jan 26, 2022Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect1
EP2661276
Aug 2, 2017Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions1

Latest PTAB cases involving Revance Therapeutics New

Discover the latest PTAB cases involving Revance Therapeutics, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 8, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Revance Therapeutics

IPR2021-01204Jul 1, 2021REVANCE THERAPEUTICSMEDY TOXInstitution Denied
IPR2021-01203Jul 1, 2021REVANCE THERAPEUTICSMEDY TOXInstitution Denied

Top competitors of Revance Therapeutics

Top competitors of Revance Therapeutics based on patent oppositions.